AIP
PTCT icon

Arrowpoint Investment Partners’s PTC Therapeutics PTCT Stock Holding History

Arrowpoint Investment Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7M Buy
39,701
+30,463
+330% +$2.16M 2.4% 12
2025
Q4 		$702K Buy
9,238
+5,947
+181% +$432K 0.1% 59
2025
Q3 		$202K Buy
+3,291
New +$171K 0.2% 66

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Arrowpoint Investment Partners's PTCT Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its PTC Therapeutics (PTCT) stake by 330% in Q1 2026, buying an estimated $2.16M and bringing the position to 39,701 shares worth $2.7M. The position accounts for 2.4% of the portfolio, ranked #12.

Arrowpoint Investment Partners first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Arrowpoint Investment Partners held 39,701 shares of PTC Therapeutics worth $2.7M as of Q1 2026.
  • Arrowpoint Investment Partners bought 30,463 PTC Therapeutics shares in Q1 2026, an estimated $2.16M.
  • PTC Therapeutics made up 2.4% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #12 holding.
  • Arrowpoint Investment Partners first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.